# BCX9930 for the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) in Participants With Inadequate Response to C5 Inhibitor Therapy

> **NCT05116774** · PHASE2 · TERMINATED · sponsor: **BioCryst Pharmaceuticals** · enrollment: 12 (actual)

## Conditions studied

- Paroxysmal Nocturnal Hemoglobinuria (PNH)

## Interventions

- **DRUG:** Eculizumab
- **DRUG:** Ravulizumab
- **DRUG:** BCX9930

## Key facts

- **NCT ID:** NCT05116774
- **Lead sponsor:** BioCryst Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-12-06
- **Primary completion:** 2023-09-14
- **Final completion:** 2023-09-14
- **Target enrollment:** 12 (ACTUAL)
- **Why stopped:** Sponsor decision
- **Last updated:** 2025-03-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05116774

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05116774, "BCX9930 for the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) in Participants With Inadequate Response to C5 Inhibitor Therapy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05116774. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*